{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:22Z","timestamp":1792931962626,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01377-8","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:07:15Z","timestamp":1761052035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Danish nationwide population-based cohort study on acute myeloid leukemia with RUNX1::RUNX1T1 \u2013 Real-world outcomes and clinicopathological characteristics"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0347-711X","authenticated-orcid":false,"given":"Johannes Frasez","family":"Soerensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6753-7051","authenticated-orcid":false,"given":"Daniel Tuyet","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-7155","authenticated-orcid":false,"given":"Andreas Due","family":"\u00d8rskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-1297","authenticated-orcid":false,"given":"Dennis Lund","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0122","authenticated-orcid":false,"given":"Anni","family":"Aggerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Stidsholt","family":"Roug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-3271","authenticated-orcid":false,"given":"Maja","family":"Ludvigsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1377_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"1377_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1377_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","volume":"4","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4:66\u201375.","journal-title":"Blood Adv"},{"key":"1377_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369\u201377.","journal-title":"J Clin Oncol"},{"key":"1377_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u201396.","journal-title":"Lancet Oncol"},{"key":"1377_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1200\/JCO.23.00943","volume":"42","author":"NH Russell","year":"2024","unstructured":"Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, et al. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol. 2024;42:1158\u201368.","journal-title":"J Clin Oncol"},{"key":"1377_CR8","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508\u201316.","journal-title":"Lancet"},{"key":"1377_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terr\u00e9 C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113\u20139.","journal-title":"Haematologica"},{"key":"1377_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ejh.13626","volume":"107","author":"A Bouvier","year":"2021","unstructured":"Bouvier A, Hamel JF, Delaunay J, Delabesse E, Dumas PY, Ledoux MP, et al. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS\/FILO acute myeloid leukemia 2006-intermediate-risk trial. Eur J Haematol. 2021;107:111\u201321.","journal-title":"Eur J Haematol"},{"key":"1377_CR11","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854\u201360.","journal-title":"Blood"},{"key":"1377_CR12","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"G Borthakur","year":"2022","unstructured":"Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, et al. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022;97:1427\u201334.","journal-title":"Am J Hematol"},{"key":"1377_CR13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood-2014-01-549212","volume":"124","author":"MA Hospital","year":"2014","unstructured":"Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, et al. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood. 2014;124:1312\u20139.","journal-title":"Blood"},{"key":"1377_CR14","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41375-024-02335-2","volume":"38","author":"C Orvain","year":"2024","unstructured":"Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas PY, Iat A, et al. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study. Leukemia. 2024;38:1949\u201357.","journal-title":"Leukemia"},{"key":"1377_CR15","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","volume":"127","author":"N Duployez","year":"2016","unstructured":"Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127:2451\u20139.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01377-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01377-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01377-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:23:34Z","timestamp":1788787414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01377-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01377-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the supplementary file (fig. 1) has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F.S.; A.D.R.; M.L.: No conflicts of interest to declare. D.T.K.: Consulting\/advisory board: AbbVie, Astellas Pharma, Immedica pharma AB, Sevier; travel grants: Swedish Orphan Biovitrum; Research funding: unrestricted grant from Incyte Biosciences Nordic AB. A.S.R.: Jazz Pharmaceuticals: Travel grant, Daichii Sankyo: Consultancy fee, Immedica, Consultancy fee, unrestricted research grant, AbbVie: Consultancy fee. Servier: Consultancy fee. D.L.H.: Has served as Advisory Board member for Janssen and Takeda, Travel grants: EUSA Pharma, Alexion and SoBI outside this work. K.G.: Unrestricted research grants from Janssen Pharma and Medac. Not related to the current project.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Central Denmark Region Committees on Health Research Ethics (record no. 1-10-72-123-22) and conducted in accordance with Danish law. There was given exemption from informed consent in accordance with the Danish Health Care Act and the Decree on Information and Consent to Participation in Health Research Projects and on Reporting Supervision of Health Research Projects.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"171"}}